


CLAIMS

1. A solid amorphous dispersion comprising:

a) about 40 % w/w to about 80 % w/w of a compound of formula (I):




or a pharmaceutically acceptable salt thereof, in the dispersion; and

b) a polymer excipient.

2. The solid amorphous dispersion of claim 1, comprising i) about 40 % w/w to about 70 % w/w of the compound of formula (I), or a pharmaceutically acceptable salt thereof in the dispersion; ii) about 40 % w/w to about 60 % w/w of the compound of formula (I), or a pharmaceutically acceptable salt thereof in the dispersion; iii) about 45 % w/w to about 55 % w/w of the compound of formula (I), or a pharmaceutically acceptable salt thereof in the dispersion; iv) about 50 % w/w of the compound of formula (I), or a pharmaceutically acceptable salt thereof in the dispersion; v) about 60 % w/w of the compound of formula (I), or a pharmaceutically acceptable salt thereof in the dispersion; or vi) about 70 % w/w of the compound of formula (I), or a pharmaceutically acceptable salt thereof in the dispersion.
3. The solid amorphous dispersion of claim 1 or 2, wherein the polymer excipient is hydroxypropyl methylcellulose (HPMC), a copolymer comprising methacrylic acid, a copolymer comprising vinyl acetate and N-vinyl-2-pyrrolidone, optionally wherein the polymer excipient is: i) hydroxypropyl methylcellulose acetate succinate (HPMC AS), optionally wherein the HPMC AS is HPMC AS L grade (HPMC AS-L); ii) a copolymer comprising methacrylic acid and methyl methacrylate, or a copolymer comprising N,N-dimethylaminoethyl methacrylate, methylmethacrylate, and butylmethacrylate; or iii) a copolymer comprising methacrylic acid and ethylacrylate,

optionally wherein the copolymer is a copolymer of about 1.4:1 to about 1:1.4 methacrylic acid and ethylacrylate, a copolymer of about 1.2:1 to about 1:1.2 methacrylic acid and ethylacrylate, or a copolymer of 1:1 methacrylic acid and ethylacrylate.

4. The solid amorphous dispersion of any one of claims 1-3, further comprising a crystallization inhibiting polymer (CIP), optionally wherein the CIP is methyl cellulose or HPMC.
5. The solid amorphous dispersion of claim 4, comprising i) about 5 % w/w to about 30 % w/w of the crystallization inhibiting polymer in the dispersion; ii) about 10 % w/w to about 30% w/w of the crystallization inhibiting polymer in the dispersion; iii) about 20 % w/w to about 30% w/w of the crystallization inhibiting polymer in the dispersion; iv) about 25 % w/w of the crystallization inhibiting polymer in the dispersion.
6. The solid amorphous dispersion of claim 1, comprising:
 - a) a compound of formula (I):



or a pharmaceutically acceptable salt thereof, in an amount of about 40% w/w to about 60% w/w of the dispersion; and


b) a polymer excipient in an amount of about 40% to about 60% w/w of the dispersion, optionally wherein the polymer excipient is hydroxypropyl methylcellulose (HPMC), a copolymer comprising methacrylic acid, or a copolymer comprising vinyl acetate and N-vinyl-2-pyrrolidone;

optionally wherein the polymer excipient is present in about 50% w/w in the dispersion; and

optionally wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in i) about 45 % w/w to about 55 % w/w in the dispersion; or ii) about 50 % w/w in the dispersion.

7. A composition comprising a solid amorphous dispersion comprising:

a) at least 150 mg of a compound of formula (I):



or a pharmaceutically acceptable salt thereof; and


b) a polymer excipient.

8. The composition of claim 7, further comprising a diluent or filler, optionally wherein the diluent or filler is a mixture of two or more diluents or fillers.
9. The composition of claim 8, wherein the diluent or filler is in an amount of i) about 20-35% w/w of the composition or ii) about 15-40% w/w of the composition, optionally wherein the diluent or filler is microcrystalline cellulose, silicified microcrystalline cellulose, or powdered cellulose.
10. The composition of any one of claims 7-9, further comprising a disintegrant, optionally wherein the disintegrant is a mixture of two or more diluents.
11. The composition of claim 10, wherein the disintegrant is in an amount of i) about 1-10% w/w of the composition; or ii) about 3-8% w/w of the composition, optionally wherein the disintegrant is croscarmellose sodium.
12. The composition of any one of claims 7-11, further comprising a lubricant, optionally wherein the lubricant is a mixture of two or more lubricants.

13. The composition of claim 12, wherein the lubricant is an amount of i) about 0.5-4% w/w of the composition; or ii) about 1-3% w/w of the composition, optionally wherein the lubricant is sodium lauryl sulphate, magnesium stearate, or sodium stearyl fumarate.
14. The composition of any one of claims 7-13, further comprising a crystallization inhibiting polymer, optionally wherein the crystallization inhibiting polymer is in an amount of i) about 10-30% w/w of the composition; or ii) about 15-25% w/w of the composition.
15. The composition of claim 7, comprising:

a) a solid amorphous dispersion comprising

i) at least 150 mg of a compound of formula (I):



or a pharmaceutically acceptable salt thereof; and

ii) a polymer excipient in an amount of about 15-25% w/w of the composition;

- b) a crystallization inhibiting polymer in an amount of about 15-25% w/w of the composition;
- c) a diluent or filler in an amount of about 20-35% of the composition;
- d) a disintegrant in an amount of about 3-8% w/w of the composition; and
- e) a lubricant in an amount of about 1-3% w/w of the composition.

16. The composition of claim 15, wherein:

the polymer excipient is a copolymer comprising methacrylic acid and ethylacrylate;
and/or

the crystallization inhibiting polymer is hydroxypropyl methylcellulose acetate
succinate; and/or

the diluent or filler is silicified microcrystalline cellulose; and/or

the disintegrant is croscarmellose sodium; and/or

the lubricant is sodium lauryl sulfate or sodium stearyl fumarate, or a mixture thereof.

17. A solid oral dosage form comprising a solid amorphous dispersion of any one of claims 1-6 or a composition of any one of claims 7-16.
18. The oral dosage form of claim 17, wherein the oral dosage form is a tablet, optionally comprising a coating film.
19. The oral dosage form of claim 17 or 18, comprising about 200 mg of the compound of formula (I), or a pharmaceutically acceptable salt thereof.
20. A composition of any one of claims 7-16 or a solid oral dosage form of claim 17 or 18, for use in therapy.
21. Use of a composition of any one of claims 7-16 or a solid oral dosage form of claim 17 or 18 in the manufacturing of a medicament for treating cancer in an individual in need thereof, optionally wherein the cancer is head and neck cancer, lung cancer, liver cancer, breast cancer, skin cancer, kidney cancer, testicular cancer, colon cancer, rectal cancer, gastric cancer, skin cancer, metastatic melanoma, prostate cancer, ovarian cancer, cervical cancer, bone cancer, spleen cancer, gall bladder cancer, brain cancer, pancreatic cancer, stomach cancer, anal cancer, prostate cancer, multiple myeloma, post-transplant lymphoproliferative disease, restenosis, myelodysplastic syndrome, leukemia, or lymphoma.
22. Use of a composition of any one of claims 7-16 or a solid oral dosage form of claim 17 or 18 in the manufacturing of a medicament for treating fibrosis in an individual in need thereof, optionally wherein the fibrosis is pulmonary fibrosis, bone marrow fibrosis, intestine fibrosis, pancreatic fibrosis, joint fibrosis, liver fibrosis,

retroperitoneum, kidney fibrosis, myelofibrosis, dermal fibrosis, non-alcoholic fatty liver disease, steatohepatitis, or systemic sclerosis.

23. Use of a composition of any one of claims 7-16 or a solid oral dosage form of claim 17 or 18 in the manufacturing of a medicament for treating:

i) an inflammatory disease or disorder in an individual in need thereof, optionally wherein the inflammatory disease or disorder is inflammatory bowel disease, ulcerative colitis, psoriasis, uveitis, scleritis, multiple sclerosis, pancreatitis, or asthma;


ii) chemotherapy-induced peripheral neuropathy, diabetic neuropathy, or familial amyloid polyneuropathy in an individual in need thereof;

iii) cachexia in an individual in need thereof; or

iv) anaphylaxis in an individual in need thereof.

24. A method of preparing a solid amorphous dispersion comprising

a) a compound of formula (I):



or a pharmaceutically acceptable salt thereof, and

b) a polymer excipient, the method comprising:

i) dissolving the compound of formula (I), or a pharmaceutically acceptable salt thereof, and the polymer excipient in a solvent to form a solution, optionally further comprising dissolving a crystallization inhibiting polymer; and

ii) atomizing the solution of step (i) into a drying chamber in a spray dried dispersion apparatus to prepare the solid amorphous dispersion.